Next Article in Journal
Variants of Oxidized Regenerated Cellulose and Their Distinct Effects on Neuronal Tissue
Next Article in Special Issue
Comparison of FACS and PCR for Detection of BCMA-CAR-T Cells
Previous Article in Journal
Overexpression of lipA or glpD_RuBisCO in the Synechocystis sp. PCC 6803 Mutant Lacking the Aas Gene Enhances Free Fatty-Acid Secretion and Intracellular Lipid Accumulation
Previous Article in Special Issue
Targeted Therapeutic Approach Based on Understanding of Aberrant Molecular Pathways Leading to Leukemic Proliferation in Patients with Acute Myeloid Leukemia
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 22
Issue 21
10.3390/ijms222111470
Review Report
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders

Int. J. Mol. Sci. 2021, 22(21), 11470; https://doi.org/10.3390/ijms222111470
by Jana Mihályová 1,2,*, Katarína Hradská 1, Tomáš Jelínek 1,2, Benjamin Motais 2, Piotr Celichowski 2 and Roman Hájek 1,2
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Int. J. Mol. Sci. 2021, 22(21), 11470; https://doi.org/10.3390/ijms222111470
Submission received: 19 September 2021 / Revised: 17 October 2021 / Accepted: 20 October 2021 / Published: 25 October 2021
(This article belongs to the Special Issue Novel Approaches to Hematologic Malignancies by Immunotherapy)

Round 1

Reviewer 1 Report

The review article of Mihályová J et al on the role of antibody-drug conjugates (ADCs) and bispecific antibodies (bsAbs) in B-NHL and CLL treatment is interesting because it deals with one of the most current challenges in cancer therapy.

Some changes are important to improve the work:

  • Page 3: transform the last part of paragraph Antibody-drug conjugates (from "As of 2021 onwards ...) into a table listing the nine approved ADCs.
  • Page 6: move the sentence that mentions tables 1 and 2 (Results of phase I/II clinical…) to the end of paragraph 2, allowing the reader to progressively visualize in the table what is described in the text.
  • Page 6: I would suggest that the authors add a figure in the paragraph 4 to graphically illustrate the different formats of bsAbs.
  • Page 9: as for the previous comment on tables 1 and 2, move the sentence that mentions tables 3 and 4 to the beginning of paragraph 4.1
  • Page 9: Add in the references section the citation of Webster et al 2019, present in the text.
  • Renumber the paragraphs: 3.1 is 2.1, 3.1.1 is 2.1.1 and so on.
  • Please correct typographical errors throughout the text.

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Reviewer 2 Report

The Authors provide a narrative review on the role of antibody-drug conjugates and bispecific antibodies in the treatment of B-cell NHL and CLL, focusing on mechanism of action, treatment-related toxicities, pre-clinical results and clinical trials. At first glance, this is a well-written reviewe article, with a clear outline and a straightforward informative path. The authors should be commended for this effort. Few minor comments:

 

  • Please clearly identify and state: population, intervention, comparator, outcome, timing and setting (PICOTS).
  • Please provide some information for the search strategy that has been employed for the present review article.

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Back to TopTop